Impact of periprocedural morphine use on mortality in STEMI patients treated with primary PCI.

<h4>Background</h4>Intravenous morphine (MO) decreases the effect of all oral platelet P2Y12 receptor inhibitors in vitro and observational reports suggest that its use may be associated with larger infarct size. Yet, there are limited data available about the impact of this interaction...

Full description

Bibliographic Details
Main Authors: Dominika Domokos, Andras Szabo, Gyongyver Banhegyi, Laszlo Major, Robert Gabor Kiss, David Becker, Istvan Ferenc Edes, Zoltan Ruzsa, Bela Merkely, Istvan Hizoh
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2021-01-01
Series:PLoS ONE
Online Access:https://doi.org/10.1371/journal.pone.0245433
_version_ 1818361800798765056
author Dominika Domokos
Andras Szabo
Gyongyver Banhegyi
Laszlo Major
Robert Gabor Kiss
David Becker
Istvan Ferenc Edes
Zoltan Ruzsa
Bela Merkely
Istvan Hizoh
author_facet Dominika Domokos
Andras Szabo
Gyongyver Banhegyi
Laszlo Major
Robert Gabor Kiss
David Becker
Istvan Ferenc Edes
Zoltan Ruzsa
Bela Merkely
Istvan Hizoh
author_sort Dominika Domokos
collection DOAJ
description <h4>Background</h4>Intravenous morphine (MO) decreases the effect of all oral platelet P2Y12 receptor inhibitors in vitro and observational reports suggest that its use may be associated with larger infarct size. Yet, there are limited data available about the impact of this interaction on clinical outcomes. We studied the effect of MO on mortality in ST-segment elevation myocardial infarction (STEMI) patients treated with primary PCI using a prospective registry.<h4>Methods</h4>Of the 1255 patients who underwent primary PCI, 397 received MO based on physician's judgment. Clopidogrel was used as P2Y12 receptor antagonist in all cases. Median follow-up time was 7.5 years with 457 deaths. To adjust for confounding, two propensity score-based procedures were performed: 1 to 1 matching (PSM, 728 cases), and inverse probability of treatment weighting (IPTW) retaining data from all patients. Primary outcome measure was time to all-cause death, whereas predischarge left ventricular ejection fraction (LVEF) was used as secondary end point.<h4>Results</h4>An adequate balance on baseline covariates was achieved by both methods. We found no difference in survival as the HR (MO/no MO) was 0.98 (95% confidence interval [CI]: 0.76-1.26), p = 0.86 using PSM and 1.01 (95% CI: 0.84-1.23), p = 0.88 with IPTW. Likewise, distributions of LVEFs were similar using either methods: with PSM, median LVEFs were 50.0% (interquartile range [IQR]: 43.0%-55.3%) vs 50.0% (IQR: 42.0%-55.0%) in the no MO and MO groups, respectively (p = 0.76), whereas using IPTW, they were 50.0% (IQR: 42.5%-55.0%) vs 50.0% (IQR: 41.0%-55.0%), respectively (p = 0.86).<h4>Conclusions</h4>Our data suggest that morphine use may have no impact on long-term mortality and on predischarge ejection fraction in STEMI patients treated with primary PCI.
first_indexed 2024-12-13T21:22:27Z
format Article
id doaj.art-b3f755dc24544b91864071f8c78dc6ff
institution Directory Open Access Journal
issn 1932-6203
language English
last_indexed 2024-12-13T21:22:27Z
publishDate 2021-01-01
publisher Public Library of Science (PLoS)
record_format Article
series PLoS ONE
spelling doaj.art-b3f755dc24544b91864071f8c78dc6ff2022-12-21T23:31:04ZengPublic Library of Science (PLoS)PLoS ONE1932-62032021-01-01161e024543310.1371/journal.pone.0245433Impact of periprocedural morphine use on mortality in STEMI patients treated with primary PCI.Dominika DomokosAndras SzaboGyongyver BanhegyiLaszlo MajorRobert Gabor KissDavid BeckerIstvan Ferenc EdesZoltan RuzsaBela MerkelyIstvan Hizoh<h4>Background</h4>Intravenous morphine (MO) decreases the effect of all oral platelet P2Y12 receptor inhibitors in vitro and observational reports suggest that its use may be associated with larger infarct size. Yet, there are limited data available about the impact of this interaction on clinical outcomes. We studied the effect of MO on mortality in ST-segment elevation myocardial infarction (STEMI) patients treated with primary PCI using a prospective registry.<h4>Methods</h4>Of the 1255 patients who underwent primary PCI, 397 received MO based on physician's judgment. Clopidogrel was used as P2Y12 receptor antagonist in all cases. Median follow-up time was 7.5 years with 457 deaths. To adjust for confounding, two propensity score-based procedures were performed: 1 to 1 matching (PSM, 728 cases), and inverse probability of treatment weighting (IPTW) retaining data from all patients. Primary outcome measure was time to all-cause death, whereas predischarge left ventricular ejection fraction (LVEF) was used as secondary end point.<h4>Results</h4>An adequate balance on baseline covariates was achieved by both methods. We found no difference in survival as the HR (MO/no MO) was 0.98 (95% confidence interval [CI]: 0.76-1.26), p = 0.86 using PSM and 1.01 (95% CI: 0.84-1.23), p = 0.88 with IPTW. Likewise, distributions of LVEFs were similar using either methods: with PSM, median LVEFs were 50.0% (interquartile range [IQR]: 43.0%-55.3%) vs 50.0% (IQR: 42.0%-55.0%) in the no MO and MO groups, respectively (p = 0.76), whereas using IPTW, they were 50.0% (IQR: 42.5%-55.0%) vs 50.0% (IQR: 41.0%-55.0%), respectively (p = 0.86).<h4>Conclusions</h4>Our data suggest that morphine use may have no impact on long-term mortality and on predischarge ejection fraction in STEMI patients treated with primary PCI.https://doi.org/10.1371/journal.pone.0245433
spellingShingle Dominika Domokos
Andras Szabo
Gyongyver Banhegyi
Laszlo Major
Robert Gabor Kiss
David Becker
Istvan Ferenc Edes
Zoltan Ruzsa
Bela Merkely
Istvan Hizoh
Impact of periprocedural morphine use on mortality in STEMI patients treated with primary PCI.
PLoS ONE
title Impact of periprocedural morphine use on mortality in STEMI patients treated with primary PCI.
title_full Impact of periprocedural morphine use on mortality in STEMI patients treated with primary PCI.
title_fullStr Impact of periprocedural morphine use on mortality in STEMI patients treated with primary PCI.
title_full_unstemmed Impact of periprocedural morphine use on mortality in STEMI patients treated with primary PCI.
title_short Impact of periprocedural morphine use on mortality in STEMI patients treated with primary PCI.
title_sort impact of periprocedural morphine use on mortality in stemi patients treated with primary pci
url https://doi.org/10.1371/journal.pone.0245433
work_keys_str_mv AT dominikadomokos impactofperiproceduralmorphineuseonmortalityinstemipatientstreatedwithprimarypci
AT andrasszabo impactofperiproceduralmorphineuseonmortalityinstemipatientstreatedwithprimarypci
AT gyongyverbanhegyi impactofperiproceduralmorphineuseonmortalityinstemipatientstreatedwithprimarypci
AT laszlomajor impactofperiproceduralmorphineuseonmortalityinstemipatientstreatedwithprimarypci
AT robertgaborkiss impactofperiproceduralmorphineuseonmortalityinstemipatientstreatedwithprimarypci
AT davidbecker impactofperiproceduralmorphineuseonmortalityinstemipatientstreatedwithprimarypci
AT istvanferencedes impactofperiproceduralmorphineuseonmortalityinstemipatientstreatedwithprimarypci
AT zoltanruzsa impactofperiproceduralmorphineuseonmortalityinstemipatientstreatedwithprimarypci
AT belamerkely impactofperiproceduralmorphineuseonmortalityinstemipatientstreatedwithprimarypci
AT istvanhizoh impactofperiproceduralmorphineuseonmortalityinstemipatientstreatedwithprimarypci